99368-68-0

Basic information

• Product Name: 6-CHLORO-5-(TRIFLUOROMETHYL)PYRIDIN-3-AMINE
• Synonyms: 6-CHLORO-5-(TRIFLUOROMETHYL)PYRIDIN-3-AMINE;6-Chloro-5-trifluoroMethyl-pyridin-3-ylaMine;6-chloro-5-(trifluoromethyl)-3-Pyridinamine;6-Chloro-5-(trifluoromethyl)
• CAS NO: 99368-68-0
• Molecular Formula: C₆H₄ClF₃N₂
• Molecular Weight: 196.56
• Mol File: 99368-68-0.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 292℃
• Flash Point: 130℃
• Appearance: /
• Density: 1.507
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 6-CHLORO-5-(TRIFLUOROMETHYL)PYRIDIN-3-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-CHLORO-5-(TRIFLUOROMETHYL)PYRIDIN-3-AMINE(99368-68-0)
• EPA Substance Registry System: 6-CHLORO-5-(TRIFLUOROMETHYL)PYRIDIN-3-AMINE(99368-68-0)

Safety Data

• Hazardous Substances Data: 99368-68-0(Hazardous Substances Data)

Usage

General Description

6-Chloro-5-(trifluoromethyl)pyridin-3-amine is a chemical compound with the molecular formula C7H5ClF3N2. It is a chlorinated pyridine derivative that contains a trifluoromethyl group. 6-Chloro-5-(trifluoromethyl)pyridin-3-amine is used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It has a wide range of applications in the field of organic chemistry, particularly in the development of new chemical compounds with potential biological activity. 6-Chloro-5-(trifluoromethyl)pyridin-3-amine may also be used as a building block in the production of various chemical products and can be utilized as a reagent in research laboratories.

Upstream product

• 887707-23-5 2-hydroxy-3-trifluoromethyl-5-(iodo)pyridine 
• 25391-60-0 2-chloro-3-iodo-5-nitropyridine 
• 25391-58-6 2-hydroxy-3-iodo-5-nitropyridine 
• 99368-66-8 5-nitro-3-(trifluoromethyl)pyridine-2-(1H)-one 
• 22245-83-6 3-(trifluoromethyl)pyridine-2-(1H)-one 
• 65753-47-1 2-chloro-3-trifluoromethyl-pyridine 
• 99368-66-8 2-hydroxyl-5-nitro-3-(trifluoromethyl)pyridine 
• 22245-83-6 3-(trifluoromethyl)pyridin-2-ol 
• 99368-67-9 2-chloro-5-nitro-3-(trifluoromethyl)pyridine 
• 7439-89-6 iron 

Downstream Products

• 1119088-10-6 6-phenyl-5-(trifluoromethyl)pyridin-3-amine 
• 1119088-25-3 N-(6-phenyl-5-(trifluoromethyl)pyridin-3-yl)acetamide 
• 1119085-63-0 5-methyl-2-(6-phenyl-5-(trifluoromethyl)pyridin-3-ylamino)benzoic acid 
• 956104-39-5 5-(8-oxo-6-thioxo-5-(4-methylphenyl)-5,7-diazaspiro[3.4]oct-7yl)-3-trifluoromethylpyridine-2-carbonitrile 
• 956104-40-8 ARN-509 
• 951753-87-0 5-isothiocyanato-3-(trifluoromethyl)pyridine-2-carbonitrile 
• 573762-62-6 5-amino-3-(trifluoromethyl)pyridine-2-carbonitrile 
• 889944-74-5 6-chloro-2-methylpyridine-3-sulfonyl chloride 
• 928324-59-8 6-chloro-5-(trifluoromethyl)pyridine-3-sulfonyl chloride 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES

Provided herein are Heterocyclic compounds of formula (I): and pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein W, X, Y, R1, R2, and RN are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound, and methods for treating or preventing animal and human filarial worm infections and diseases.

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

ANDROGEN RECEPTOR MODULATOR FOR TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES

PROBLEM TO BE SOLVED: To provide a series of compounds that modulate the function of the nuclear hormone receptors, especially the androgen receptor. SOLUTION: The present invention relates to hydantoin compounds, methods of using such compounds in the treatment of androgen receptor-associated conditions, such as age-related diseases, for example, prostate cancer, and to pharmaceutical compositions containing such compounds. In an embodiment, a pharmaceutical composition includes a therapeutically effective amount of a compound according to the formula II, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or adjuvant. The present invention provides a series of compounds that modulate the function of the nuclear hormone receptors, especially the androgen receptor. These compounds can cause disappearance of prostate cancer cells and tumors. COPYRIGHT: (C)2016,JPOandINPIT